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study. Source population: Canadian Association of Retired Persons. Life-
time Physical Activity Questionnaire: Lifetime activity in three domains –
sport, occupation and domestic – was self-reported retrospectively via
a validated online computer-adaptive survey. For each speciﬁc activity
type (e.g., each individual sport, each occupation held) detailed questions
were asked regarding frequency, duration and intensity. Activities were
further deconstructed by time spent in major body movement type (e.g.,
walk, run, squat).
Exposures: Energy Expenditure: estimated by multiplying number of
hours spent in an activity by the average intensity of that activity, as-
signed using standardized metabolic equivalents and reported in MET-
hours/week.
Hip and knee (tibio-femoral) joint force was estimated as the product of
lifetime bodyweight, typical hip and knee force for speciﬁc activities and
time spent in speciﬁc activities, and reported in kg-hours/week. A lifetime
bodyweight trajectory was derived using current weight, weight at age
20, maximum weight, and interpolated using a lowess (non parametric
smooth) curve. The typical hip and knee joint force assigned to each
of the body movements was based on a comprehensive review of the
biomechanical literature and a survey of expert opinion.
Relative Joint Loading Index: the ratio of cumulative joint force to total
metabolic equivalent (done separately for hip and knee).
For each physical activity exposure, mean values for 5-year intervals over
a person’s lifetime, averaged over all subjects, were calculated.
Results: Complete baseline data was collected on 4,269 subjects. The
sample was 63% female with a mean age of 61.5 years and BMI of 27.5.
Overall, women had higher lifetime energy expenditure than men (126 vs
107 MET-hours/wk), and slightly higher hip (47.9 vs 43.3 kg-hrs/wk, ×100)
and knee force (54.2 vs 44.1 kg-hrs/wk, ×100). On balance of the activity
across domains, mean energy and joint force for ‘female household’
and ‘male occupation’ were similar. The higher overall scores among
women were attributable to signiﬁcantly higher energy expenditure and
joint forces from occupational activities compared to household activities
among men. Males expended approximately 2 times the mean energy
and 3 times the mean hip and knee force in sport as women; however
for both genders, sport had a much smaller contribution to joint force and
energy expenditure than the occupation and domestic domains. For both
hip and knee forces, the highest joint loading index score (most joint force
relative to energy expenditure) was for the male sport, while the lowest
score was for female occupation.
Conclusions: Joint force trajectories for the hip and knee were con-
structed from survey data, and followed expected trends by gender and
physical activity domain. These measures may help provide information
on the tolerance of the hip and knee joint to long term load. Comparing
energy expenditure trajectories to joint force trajectories revealed variation
in different population strata, indicating these measures may be useful for
separately analyzing the effects of energy expenditure and joint load on
health outcomes.
353 DISSEMINATION OF THE EULAR RECOMMENDATIONS FOR
THE MANAGEMENT OF KNEE OSTEOARTHRITIS (OA) IN
FRANCE. WHAT SAY AND WHAT DO RHEUMATOLOGISTS?
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E. Maheu1, S. Monnier2, E. Leutenegger2. 1St Antoine Hospital, Paris,
FRANCE, 2ABR Pharma – Statistician, Paris, FRANCE
Purpose: EULAR recommendations for the management of knee OA
(KOA) have been published in 2000, then 2003 and widely disseminated
in France. However, no study focused on the level of adhesion of rheuma-
tologists (RH) to these recommendations and their application in daily
clinical practice.
Objective: To compare self-declared level of adhesion of French rheuma-
tologists to the EULAR recommendations for the management of KOA
and the way they effectively manage patients in 2007.
Methods: This was a prospective observational cross-sectional study of
professional practice. RH randomly selected within a representative panel
of French RH were asked to answer a questionnaire assessing their level
of knowledge of the EULAR recommendations for knee OA and to rate
their adhesion to each of the latter (using a 0–100mm VAS). They had
then to describe 2 successive patients visiting for symptomatic knee OA,
and the treatments they prescribed. Data collected: Demographics of
RH and patients, knee OA history and level of symptoms at visit, non
pharmacologic and pharmacologic treatments prescribed on day of visit.
Statistics: descriptive: mean, median, standard deviation (sd).
Results: 214 RH from all French areas answered: mean age 50, 69%
men, 56% private ofﬁce-based, 41% both hospital- and private ofﬁce-
based. Mean number of knee OA patients seen monthly was 42. 374 pa-
tients were included: mean age 69±10 years, 66% women, BMI 29±6,
97% painful at visit, mean pain level on a VAS = 49±22mm under
treatment (93% received a pharmacological treatment), mean level of
handicap on a VAS = 49±21mm, morning stiffness in 48% of patients,
night pain in 24%, presence of knee effusion in 125 patients (33%). 38%
were at a Kellgren-Lawrence (KL) radiological grade 2, 44% at a KL 3,
9% at a KL 4. Knee OA symptoms were present for 6±5 years. Thirteen
had already undergone a total joint replacement (3%). Adhesion rates to
EULAR recommendations and prescriptions made in the “real life” appear
in the table.
Table. Comparisons of adhesion rates to EULAR recommendations for knee OA and the level of
real prescriptions by rheumatologists to patients in daily practice








Treatment combines pharmaco- and non pharmacologic 78.9 (14.2) 296 (79%)
Treatment must be individualized 78.8 (14.4) 100%
Treatment associates education, exercises, aids and
weight loss
74.1 (18.9) 303 (81%)
Paracetamol, ﬁrst line analgesic 64.4 (24.3) 109 (26%)
Topics are effective 52.2 (25.0) 87 (23%)
NSAIDs if non response/intolerance to paracetamol 71.4 (19.5) 77 (18%)
Opioids are useful alternative 64.7 (20.7) 69 (16%)
Sy-SADOA are effective on symptoms (oral/intra-articular) 66.7 (19.3) 266 (71%)
[143 (38%) oral/
123 (33%) IA]
Intra-articular steroids in case of knee ﬂare 82.1 (14.7) 55 (14.7%)
Total knee replacement if failure of medical treatment 80.2 (12.8) 21 (6%)
Conclusions: In general, EULAR recommendations for knee OA seem to
be both agreed and followed by French RH. However, the percentage of
patients receiving paracetamol is low and the number of patients having
IA steroids under the number of patients presenting with knee effusion
and/or night pain. Pain level rated by these treated patients remains over
the “patient acceptable symptom state”.
This study has partly been supported by a grant from Genevrier Labora-
tories, Soﬁa Antipolis, France.
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Purpose: EULAR recommendations for the management of knee OA
have been published in 2000, then 2003 and widely disseminated in
France. However, no study focused on the way patients were treated
since this dissemination, nor on patient’s perception of their treatment
and on their level of satisfaction or expectations.
Objective: To evaluate the level of satisfaction and expectations of knee
OA patients treated by French rheumatologists (RH) in 2007.
Methods: This was a prospective observational cross-sectional study.
RH randomly selected within a representative panel of French RH were
asked to answer a questionnaire assessing their level of knowledge of
the EULAR recommendations for knee OA and to rate their adhesion
to each. They had then to describe 2 successive patients visiting for
symptomatic knee OA, and their treatments. Patients were given by
their RH a questionnaire they had to answer at home on their level of
satisfaction and expectations with respect to the management of their
knee OA. Data collected: Demographics, knee OA history and level of
symptoms, overall satisfaction level regarding the management of their
knee OA, speciﬁc levels with respect to attention paid to pain, dysfunc-
tion, information provided, advice for daily activities, physiotherapy and
exercise, pharmacologic therapy and monitoring of potential side effects
scored on a 0–100mm VAS (0=not satisﬁed at all; 100 = completely
satisﬁed). Statistics: descriptive: mean, median, standard deviation (sd).
Results: 346 patients out of 374 (92.5%) included by 214 RH returned
their answers: mean age 69.1±9.8 years, 67% women, BMI 28.5±5.7,
pain on VAS=49.2±22.2 under treatment, presence of knee effusion in
116 patients (34%); 38% at a Kellgren-Lawrence (KL) radiological grade
2, 43% at a KL 3, 9% at a KL 4. Knee OA symptoms were present for
6.2±6.2 years; patients were followed by a practitioner for 4.5±4.6 years
(mean number of GP visited 1.3, mean number of orthopaedic surgeons
visited 0.5, mean number of RH visited 1.2).
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Levels of satisfaction rated by patients on a VAS appear in the table.
Main expectations expressed by patients were (by order of citations):
achieve pain relief (87%), slow knee OA progression (76%), reduce
physical handicap (61%), receive information on OA and its management
(16%), management of side-effects of therapies (12%), more prescrip-
tions of physiotherapy (7%).
Table 1: Levels of satisfaction rated by patients on the management of their knee OA
Outcome VAS score (mm):
m±sd
Overall level of satisfaction 69.3±23.7
Attention paid by the doctor to pain 73.0±22.3
Information on the disease and its management 71.4±22.5
Attention paid on physical handicap 69.4±23.6
Advice for daily activities 65.6±25.0
Surgery, if applicable 65.1±34.1
On pharmacological treatments efﬁcacy on pain and mobility 59.1±25.3
Physiotherapy 50.0±28.9
Conclusions: Overall, patient’s satisfaction on the management of their
knee OA was good. Attention paid to pain, functional impairment and
the requirement of information on the disease by French RH are highly
rated by patients. The lowest patient’s satisfaction scores regard efﬁcacy
of drugs and physiotherapy prescriptions.
This study has partly been supported by a grant from Genevrier Labora-
tories, Soﬁa Antipolis, France.
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Purpose: A number of differences have been noted in the past regarding
the risk for hip or knee osteoarthritis (OA). In addition, differences in both
the incidence, type and severity of disease have been noted between
men and women. In this study we investigated the role of variants in
eight genes which have been previously implicated in risk of knee OA but
not yet tested for genetic association with hip OA.
Methods: 260 men with clinical hip OA (American College of Rheumatol-
ogy criteria) and 292 age matched controls and 520 women with hip OA
and 380 age matched controls were collected in the Midlands region of
the UK. DNA samples from these individuals were genotyped at variants
in the AACT, ADAM12, CILP, COX-2, CD36, OPG, COMP and TNA genes
all of which had been previously implicated in risk of knee OA (Arthritis &
Rheumatism 2006; 54 (2): 533–539).
Results: Variants in the genes for AACT (rs4934 OR for minor al-
lele = 0.91 95%CI = 0.84−0.99), CD36 (rs1049654 OR=1.11 95%CI =
1.01−1.21) and TNA (rs13963, recessive OR=1.49 95%CI = 1.02−2.18)
were modestly associated with hip OA in women and a variant in the
CILP gene (rs2073711) was associated with hip OA in men (OR=1.23
95%CI = 1.01−1.49). A haplotype in the OPG gene (rs1564858–
rs2073618) was associated only in women (OR 1.29 95%CI = 1.06−1.56)
and a haplotype in the ADAM12 gene (rs1871054–rs3740199) was asso-
ciated only in men (OR=1.18 95%CI = 1.01−1.36). When both genders
were combined variants in the AACT (OR=0.89 95%CI 0.81−0.99), and
CD36 genes (OR=1.11 95%CI = 1.0−1.23) were signiﬁcantly associated
with risk of hip OA. With the exception of CD36 the effect sizes were all
smaller than those previously observed for knee OA.
Conclusions: Our data indicate that although there may be differences in
the genetic factors contributing to knee and hip OA there is some overlap
in gene effects at least in populations from the UK. Moreover, these data
suggest that genetic susceptibility to hip OA might affect men and women
differently.
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Purpose: Genetic risk factors are involved in knee osteoarthritis (OA), but
how genetic risk factors modify the knee joint and lead to its vulnerability
is not yet clear. Tibiofemoral malalignment is a biomechanical risk factor
involved in knee OA progression and development, but it is unclear how
tibiofemoral malalignment develops. Whether tibiofemoral malalignment
is under genetic control is the aim of the present study, wherein the
heritability of tibiofemoral alignment in sibling pairs will be investigated.
Methods: Patients from the GARP (Genetics, ARtrosis and Progression)
study, a prospective cohort study comprising sibling pairs with familial
OA at multiple joint sites, were utilized. Clinical characteristics of patients
were recorded by using standardized questionnaires. Radiographic sever-
ity of knee OA was assessed according to the Kellgren-Lawrence (KL)
method: radiographic knee OA was deﬁned as a KL score of at least 2.
Tibiofemoral anatomical angle was measured on digitized semi-ﬂexed
knee radiographs for both knees on a continuous scale. The heritability
of the tibiofemoral angle was estimated by comparing twice the sibling
variance divided by the total variance and were presented with 95%
conﬁdence intervals (95%CI). Heritability estimates were adjusted for
age, sex, body mass index, KL score and history of meniscectomy or
lower limb fracture.
Results: Three hundred sixty subjects (mean age 60 years, 81% women)
representing 180 families were studied. The mean (sd) tibiofemoral an-
gle of the right and left knees in the probands was 182.7º (2.9) and
182.8 (2.8) respectively, and in the siblings was not statistically different.
Radiographic knee OA was evident in 28.5% and 25.1% of probands
and siblings respectively. The unadjusted heritability estimates for the
tibiofemoral angle of the right and left knee were 0.48 and 0.38 respec-
tively. After adjustments estimates increased to 0.48 (95%CI 0.18−0.78)
and 0.50 (95%CI 0.21−0.79) for the right and left knee respectively.
Stratiﬁed analyses in sibling pairs with non-osteoarthritic right knees (93
sibling pairs) and left knees (109 sibling pairs) were done, revealing
adjusted heritability estimates for the tibiofemoral angle of the right and
left knees of 0.42 (95%CI 0.02−0.82) and 0.56 (95%CI 0.19−0.92).
Conclusions: High heritabilities were estimated for the tibiofemoral angle
in right and left knees, suggesting a substantial genetic component, which
was independent of clinical characteristics, radiographic knee OA or
previous injury. Tibiofemoral (mal)alignment could attribute to the genetic
predisposition for knee OA. The results of the present study need to be
conﬁrmed in other study populations.
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Purpose: Investigating the associations between plasma levels of a range
of cytokines and chemokines, Selenoprotein S (SELS) gene variation and
osteoarthritis (OA) subtypes.
Methods: The GARP study consists of 191 sibling pairs with symptomatic
OA at multiple joint sites. Previously, genetic variation at the C-reactive
protein (CRP) gene was shown to associate to serum high sensitive CRP
and hand OA in the GARP study. Recent studies showed association of
a single nucleotide polymorphism (SNP) in the SELS gene and plasma
inﬂammatory markers and CRP levels in patients with active Crohn’s
Disease and ﬁnally. To asses the relation between SELS gene variation,
inﬂammatory markers and OA subtypes in the GARP study, we have
measured plasma levels of 17 cytokines and chemokines and genetic
variation at the SELS gene.
Results: 9 out of 17 serum markers had 60% or more of the signals
above the detection limit of the method used and could be assessed
quantitatively (QN), whereas the remaining 8 markers were assessed
qualitatively (QL) using a measure of detectable versus not detectable.
The assessed levels of the QN analyzed cytokines and chemokines
and CRP levels showed substantial correlations, in order to reduce
redundancy between these markers we performed a principal component
analysis (PCA). This analysis revealed that 3 components underlie 61%
of the total plasma variation. The ﬁrst component explaining 34% of the
